The DOI matches its Crossref record; 525 of the 525 references it cites were found in a registry or an index.
Biased Receptor Signaling in Drug Discovery
Open accessAbstract
A great deal of experimental evidence suggests that ligands can stabilize different receptor active states that go on to interact with cellular signaling proteins to form a range of different complexes in varying quantities. In pleiotropically linked receptor systems, this leads to selective activation of some signaling pathways at the expense of others (biased signaling). This article summarizes the current knowledge about the complex components of receptor systems, the evidence that biased signaling is used in natural physiology to fine-tune signaling, and the current thoughts on how this mechanism may be applied to the design of better drugs. Although this is a fairly newly discovered phenomenon, theoretical and experimental data suggest that it is a ubiquitous behavior of ligands and receptors and to be expected. Biased signaling is simple to detect in vitro and there are numerous methods to quantify the effect with scales that can be used to optimize this activity in structure-activity medicinal chemistry studies. At present, the major hurdle in the application of this mechanism to therapeutics is the translation of in vitro bias to in vivo effect; this is because of the numerous factors that can modify measures of bias in natural physiologic systems. In spite of this, biased signaling still has the potential to justify revisiting of receptor targets previously thought to be intractable and also furnishes the means to pursue targets previously thought to be forbidden due to deleterious physiology (as these may be eliminated through biased signaling).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 525
Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 197
Rahmeh, R., Damian, M., Cottet, M., Orcel, H., Mendre, C., Durroux, T., Sharma, K. S., Durand, G., Pucci, B., Trinquet, E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201093109 · Cited by 196
Kofuku, Y., Ueda, T., Okude, J., Shiraishi, Y., Kondo, K., Maeda, M., Tsujishita, H., & Shimada, I. (2012) · Nature Communications · doi:10.1038/ncomms2046 · Cited by 195
Busnelli, M., Saulière, A., Manning, M., Bouvier, M., Galés, C., & Chini, B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277178 · Cited by 195
Hauser, M. A., & Legler, D. F. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.2mr0815-380r · Cited by 190
Raehal, K. M., & Bohn, L. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.08.003 · Cited by 189
Seven-Transmembrane Receptor Signaling Through β-Arrestin
Shenoy, S. K., & Lefkowitz, R. J. (2005) · Science's STKE · doi:10.1126/stke.2005/308/cm10 · Cited by 189
Baker, J. G., Hall, I. P., & Hill, S. J. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.6.1357 · Cited by 189
Identification of amino acid residues crucial for chemokine receptor dimerization
Hernanz-Falcón, P., Rodríguez-Frade, J. M., Serrano, A., Juan, D., del Sol, A., Soriano, S. F., Roncal, F., Gómez, L., Valencia, A., Martínez-A, C., et al. (2004) · Nature Immunology · doi:10.1038/ni1027 · Cited by 188
Cathepsin S Causes Inflammatory Pain via Biased Agonism of PAR2 and TRPV4
Zhao, P., Lieu, T., Barlow, N., Metcalf, M., Veldhuis, N. A., Jensen, D. D., Kocan, M., Sostegni, S., Haerteis, S., Baraznenok, V., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.599712 · Cited by 188
McLaughlin, J. N., Shen, L., Holinstat, M., Brooks, J. D., DiBenedetto, E., & Hamm, H. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414090200 · Cited by 186
Noncanonical GPCR signaling arising from a PTH receptor–arrestin–Gβγ complex
Wehbi, V. L., Stevenson, H. P., Feinstein, T. N., Calero, G., Romero, G., & Vilardaga, J.-P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205756110 · Cited by 185
Molecular Recognition by Induced Fit: How Fit is the Concept?
Bosshard, H. R. (2001) · Physiology · doi:10.1152/physiologyonline.2001.16.4.171 · Cited by 184
Dijksterhuis, J. P., Baljinnyam, B., Stanger, K., Sercan, H. O., Ji, Y., Andres, O., Rubin, J. S., Hannoush, R. N., & Schulte, G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612648 · Cited by 184
Dror, R. O., Jensen, M. Ø., Borhani, D. W., & Shaw, D. E. (2010) · Journal of General Physiology · doi:10.1085/jgp.200910373 · Cited by 179
Redfern, C. H., Coward, P., Degtyarev, M. Y., Lee, E. K., Kwa, A. T., Hennighausen, L., Bujard, H., Fishman, G. I., & Conklin, B. R. (1999) · Nature Biotechnology · doi:10.1038/6165 · Cited by 178
Gautam, N., Downes, G. B., Yan, K., & Kisselev, O. (1998) · Cellular Signalling · doi:10.1016/s0898-6568(98)00006-0 · Cited by 177
In Vivo Delta Opioid Receptor Internalization Controls Behavioral Effects of Agonists
Pradhan, A. A. A., Becker, J. A. J., Scherrer, G., Tryoen-Toth, P., Filliol, D., Matifas, A., Massotte, D., Gavériaux-Ruff, C., & Kieffer, B. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005425 · Cited by 177
G Protein-Coupled Receptors: Dynamic Machines for Signaling Pain and Itch
Geppetti, P., Veldhuis, N. A., Lieu, T., & Bunnett, N. W. (2015) · Neuron · doi:10.1016/j.neuron.2015.11.001 · Cited by 177
Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism
Castro, M., Nikolaev, V. O., Palm, D., Lohse, M. J., & Vilardaga, J.-P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503942102 · Cited by 176
Schmid, C. L., & Bohn, L. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1665-10.2010 · Cited by 175
Charest, P. G., Terrillon, S., & Bouvier, M. (2005) · EMBO reports · doi:10.1038/sj.embor.7400373 · Cited by 172
Bohn, L. M., Dykstra, L. A., Lefkowitz, R. J., Caron, M. G., & Barak, L. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.106 · Cited by 171
Alvarez, V. A., Arttamangkul, S., Dang, V., Salem, A., Whistler, J. L., von Zastrow, M., Grandy, D. K., & Williams, J. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05769.2002 · Cited by 170
Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs
McCorvy, J. D., Butler, K. V., Kelly, B., Rechsteiner, K., Karpiak, J., Betz, R. M., Kormos, B. L., Shoichet, B. K., Dror, R. O., Jin, J., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2527 · Cited by 170
How Does Arrestin Assemble MAPKs into a Signaling Complex?
Song, X., Coffa, S., Fu, H., & Gurevich, V. V. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806124200 · Cited by 169
β-Arrestin-dependent Regulation of the Cofilin Pathway Downstream of Protease-activated Receptor-2
Zoudilova, M., Kumar, P., Ge, L., Wang, P., Bokoch, G., & DeFea, K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701391200 · Cited by 169
Analysis of Allosterism in Functional Assays
Ehlert, F. J. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090886 · Cited by 168
Positive and Negative Allosteric Modulators Promote Biased Signaling at the Calcium-Sensing Receptor
Davey, A. E., Leach, K., Valant, C., Conigrave, A. D., Sexton, P. M., & Christopoulos, A. (2012) · Endocrinology · doi:10.1210/en.2011-1426 · Cited by 167
Chemokine blockers – therapeutics in the making?
Wells, T. N. C., Power, C. A., Shaw, J. P., & Proudfoot, A. E. I. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.001 · Cited by 167
Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116689257 · Cited by 166
Hill, R., Disney, A., Conibear, A., Sutcliffe, K., Dewey, W., Husbands, S., Bailey, C., Kelly, E., & Henderson, G. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14224 · Cited by 165
Ligand‐directed signalling at β‐adrenoceptors
Evans, B. A., Sato, M., Sarwar, M., Hutchinson, D. S., & Summers, R. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00602.x · Cited by 160
Atwood, B. K., Wager‐Miller, J., Haskins, C. P., Straiker, A. J., & Mackie, K. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074013 · Cited by 160
Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M., & Christopoulos, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094011 · Cited by 159
Zimmerman, B., Beautrait, A., Aguila, B., Charles, R., Escher, E., Claing, A., Bouvier, M., & Laporte, S. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002522 · Cited by 159
β-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation
Ahn, S., Kim, J., Hara, M. R., Ren, X.-R., & Lefkowitz, R. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808463200 · Cited by 159
Activation-dependent Conformational Changes in β-Arrestin 2
Xiao, K., Shenoy, S. K., Nobles, K., & Lefkowitz, R. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409785200 · Cited by 158
Corvol, J.-C., Muriel, M.-P., Valjent, E., Féger, J., Hanoun, N., Girault, J.-A., Hirsch, E. C., & Hervé, D. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0676-04.2004 · Cited by 158
Urs, N. M., Gee, S. M., Pack, T. F., McCorvy, J. D., Evron, T., Snyder, J. C., Yang, X., Rodriguiz, R. M., Borrelli, E., Wetsel, W. C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614347113 · Cited by 158
Christensen, G. L., Kelstrup, C. D., Lyngsø, C., Sarwar, U., Bøgebo, R., Sheikh, S. P., Gammeltoft, S., Olsen, J. V., & Hansen, J. L. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900550-mcp200 · Cited by 156
Poulin, B., Butcher, A. J., McWilliams, P., Bourgognon, J.-M., Pawlak, R., Kong, K. C., Bottrill, A. R., Mistry, S. C., Wess, J., Rosethorne, E. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914801107 · Cited by 156
Real-time trafficking and signaling of the glucagon-like peptide-1 receptor
Roed, S. N., Wismann, P., Underwood, C. R., Kulahin, N., Iversen, H., Cappelen, K. A., Schäffer, L., Lehtonen, J., Hecksher-Soerensen, J., Secher, A., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.11.010 · Cited by 153
New concepts in pharmacological efficacy at 7 TM receptors: IUPHAR R eview 2
Kenakin, T. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02223.x · Cited by 153
Self-citationMolecular Spies for Bioimaging—Fluorescent Protein-Based Probes
Miyawaki, A., & Niino, Y. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.03.002 · Cited by 152
Welihinda, A. A., Kaur, M., Greene, K., Zhai, Y., & Amento, E. P. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.02.010 · Cited by 152
Yang, P. B., Maguire, J. J., & Davenport, A. P. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.002 · Cited by 150
Targeting of Diacylglycerol Degradation to M1 Muscarinic Receptors by ß-Arrestins
Nelson, C. D., Perry, S. J., Regier, D. S., Prescott, S. M., Topham, M. K., & Lefkowitz, R. J. (2007) · Science · doi:10.1126/science.1134562 · Cited by 150
Huang, X., Setola, V., Yadav, P. N., Allen, J., Rogan, S. C., Hanson, B. J., Revankar, C. M., Robers, M., Doucette, C., & Roth, B. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.058057 · Cited by 150
Kuna, R. S., Girada, S. B., Asalla, S., Vallentyne, J., Maddika, S., Patterson, J. T., Smiley, D. L., DiMarchi, R. D., & Mitra, P. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2012 · Cited by 150
Pang, P. S., Butler, J., Collins, S. P., Cotter, G., Davison, B. A., Ezekowitz, J. A., Filippatos, G. S., Levy, P. D., Metra, M., Ponikowski, P. P., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx196 · Cited by 149
Luttrell, L. M. (2008) · Molecular Biotechnology · doi:10.1007/s12033-008-9031-1 · Cited by 148
Multiple mechanisms of serotonergic signal transduction
Roth, B. L., & Chuang, D. M. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90621-7 · Cited by 148
Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor
Khajehali, E., Malone, D. T., Glass, M., Sexton, P. M., Christopoulos, A., & Leach, K. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099192 · Cited by 147
Tan, L., Yan, W., McCorvy, J. D., & Cheng, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00435 · Cited by 147
Ubiquitination of β-Arrestin Links Seven-transmembrane Receptor Endocytosis and ERK Activation
Shenoy, S. K., Barak, L. S., Xiao, K., Ahn, S., Berthouze, M., Shukla, A. K., Luttrell, L. M., & Lefkowitz, R. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700852200 · Cited by 146
Strachan, R. T., Sun, J., Rominger, D. H., Violin, J. D., Ahn, S., Thomsen, A. R. B., Zhu, X., Kleist, A. B., Costa, T., & Lefkowitz, R. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548131 · Cited by 146
Identification of Novel Functionally Selective κ-Opioid Receptor Scaffolds
White, K. L., Scopton, A. P., Rives, M., Bikbulatov, R. V., Polepally, P. R., Brown, P. J., Kenakin, T., Javitch, J. A., Zjawiony, J. K., & Roth, B. L. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.089649 · Cited by 146
Self-citationEmerging Functional Divergence of β-Arrestin Isoforms in GPCR Function
Srivastava, A., Gupta, B., Gupta, C., & Shukla, A. K. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.001 · Cited by 145
β-Arrestins regulate a Ral-GDS–Ral effector pathway that mediates cytoskeletal reorganization
Bhattacharya, M. M., Anborgh, P. H., Babwah, A. V., Dale, L. B., Dobránsky, T., Benovic, J. L., Feldman, R. D., Verdi, J. M., Rylett, R. J., & Ferguson, S. S. G. (2002) · Nature Cell Biology · doi:10.1038/ncb821 · Cited by 144
West, G. M., Chien, E. Y. T., Katritch, V., Gatchalian, J., Chalmers, M. J., Stevens, R. C., & Griffin, P. R. (2011) · Structure · doi:10.1016/j.str.2011.08.001 · Cited by 143
Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs
Dong, S., Rogan, S. C., & Roth, B. L. (2010) · Nature Protocols · doi:10.1038/nprot.2009.239 · Cited by 143
Qin, C. X., May, L. T., Li, R., Cao, N., Rosli, S., Deo, M., Alexander, A. E., Horlock, D., Bourke, J. E., Yang, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms14232 · Cited by 143
The Active Conformation of β-Arrestin1
Nobles, K. N., Guan, Z., Xiao, K., Oas, T. G., & Lefkowitz, R. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611483200 · Cited by 142
Small Molecule Disruption of Gβγ Signaling Inhibits the Progression of Heart Failure
Casey, L. M., Pistner, A. R., Belmonte, S. L., Migdalovich, D., Stolpnik, O., Nwakanma, F. E., Vorobiof, G., Dunaevsky, O., Matavel, A., Lopes, C. M. B., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.217075 · Cited by 140
Efficacy and ligand bias at the μ‐opioid receptor
Kelly, E. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12222 · Cited by 139
Cao, T. T., Mays, R. W., & von Zastrow, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24592 · Cited by 138
Minireview: More Than Just a Hammer: Ligand “Bias” and Pharmaceutical Discovery
Luttrell, L. M. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1314 · Cited by 136
Ishikawa, Y., Sorota, S., Kiuchi, K., Shannon, R. P., Komamura, K., Katsushika, S., Vatner, D. E., Vatner, S. F., & Homcy, C. J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117219 · Cited by 135
Trinquet, E., Fink, M., Bazin, H., Grillet, F., Maurin, F., Bourrier, E., Ansanay, H., Leroy, C., Michaud, A., Durroux, T., et al. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.08.002 · Cited by 135
Conformational Selection Is a Dominant Mechanism of Ligand Binding
Vogt, A. D., & Di, E. (2013) · Biochemistry · doi:10.1021/bi400929b · Cited by 135
Aurelio, L., Valant, C., Flynn, B. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9002582 · Cited by 134
Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy
Furness, S. G. B., Liang, Y.-L., Nowell, C. J., Halls, M. L., Wookey, P. J., Dal Maso, E., Inoue, A., Christopoulos, A., Wootten, D., & Sexton, P. M. (2016) · Cell · doi:10.1016/j.cell.2016.09.021 · Cited by 134
Bone Response to Intermittent Parathyroid Hormone Is Altered in Mice Null for β-Arrestin2
Ferrari, S., Pierroz, D. D., Glatt, V., Goddard, D. S., Bianchi, E. N., Lin, F., Manen, D., & Bouxsein, M. (2005) · Endocrinology · doi:10.1210/en.2004-1282 · Cited by 131
G Protein-Coupled Receptors in and on the Cell Nucleus: A New Signaling Paradigm?
Boivin, B., Vaniotis, G., Allen, B. G., & Hébert, T. E. (2008) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890801941889 · Cited by 130
Jørgensen, R., Kubale, V., Vrecl, M., Schwartz, T. W., & Elling, C. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120006 · Cited by 130
Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth
Duhr, F., Déléris, P., Raynaud, F., Sevéno, M., Morisset‐Lopez, S., la Cour, C. M., Millan, M. J., Bockaert, J., Marin, P., & Chaumont‐Dubel, S. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1547 · Cited by 129
Gurwitz, D., Haring, R., Heldman, E., Fraser, C. M., Manor, D., & Fisher, A. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90220-8 · Cited by 129
Genetically Encoded Fluorescent Biosensors for Live-Cell Visualization of Protein Phosphorylation
Oldach, L., & Zhang, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.12.012 · Cited by 128
Chen, X., Sassano, M. F., Zheng, L., Setola, V., Chen, M., Bai, X., Frye, S. V., Wetsel, W. C., Roth, B. L., & Jin, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300603y · Cited by 127
GS Activation Is Time-limiting in Initiating Receptor-mediated Signaling
Hein, P., Rochais, F., Hoffmann, C., Dorsch, S., Nikolaev, V. O., Engelhardt, S. H., Berlot, C. H., Lohse, M. J., & Bünemann, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606713200 · Cited by 127
Differentiation of Opioid Drug Effects by Hierarchical Multi-Site Phosphorylation
Just, S., Illing, S., Trester-Zedlitz, M., Lau, E. K., Kotowski, S. J., Miess, E., Mann, A., Doll, C., Trinidad, J. C., Burlingame, A. L., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.082875 · Cited by 127
Lee, Y., Basith, S., & Choi, S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01453 · Cited by 126
Wilden, U. (1995) · Biochemistry · doi:10.1021/bi00004a040 · Cited by 124
Urs, N. M., Daigle, T. L., & Caron, M. G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.186 · Cited by 122
Visual Pigment Gene Structure and the Severity of Color Vision Defects
Neitz, J., Neitz, M., & Kainz, P. M. (1996) · Science · doi:10.1126/science.274.5288.801 · Cited by 121
Peters, M. F., & Scott, C. W. (2009) · SLAS DISCOVERY · doi:10.1177/1087057108330115 · Cited by 121
Mahon, M. J., & Segre, G. V. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313229200 · Cited by 120
Valant, C., May, L. T., Aurelio, L., Chuo, C. H., White, P. J., Baltos, J., Sexton, P. M., Scammells, P. J., & Christopoulos, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320962111 · Cited by 119
Kenakin, T., & Morgan, P. H. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10934-6 · Cited by 119
Self-citationBiased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology
Bologna, Z., Teoh, J., Bayoumi, A., Tang, Y., & Kim, I. (2016) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.165 · Cited by 117
Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates
Baker, J. G., & Hill, S. J. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.011 · Cited by 116
β-arrestin–biased signaling through the β 2 -adrenergic receptor promotes cardiomyocyte contraction
Carr, R., Schilling, J., Song, J., Carter, R. L., Du, Y., Yoo, S. M., Traynham, C. J., Koch, W. J., Cheung, J. Y., Tilley, D. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606267113 · Cited by 113
Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling
M’Kadmi, C., Leyris, J.-P., Onfroy, L., Galès, C., Saulière, A., Gagne, D., Damian, M., Mary, S., Maingot, M., Denoyelle, S., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.659250 · Cited by 112
Galandrin, S., Denis, C., Boularan, C., Marie, J., M’Kadmi, C., Pilette, C., Dubroca, C., Nicaise, Y., Séguélas, M., N’Guyen, D., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08118 · Cited by 112
Osteoblast expression of an engineered G s -coupled receptor dramatically increases bone mass
Hsiao, E. C., Boudignon, B. M., Chang, W. C., Bencsik, M., Peng, J. C., Nguyen, T., Manalac, C., Halloran, B. P., Conklin, B. R., & Nissenson, R. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707457105 · Cited by 111
Rives, M., Rossillo, M., Liu‐Chen, L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.387332 · Cited by 111
Berchiche, Y. A., & Sakmar, T. P. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105502 · Cited by 111
The role of conformational ensembles of seven transmembrane receptors in functional selectivity
Vaidehi, N., & Kenakin, T. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.09.004 · Cited by 110
Self-citationTeixeira, L. B., Parreiras‐e‐Silva, L. T., Bruder-Nascimento, T. B., Duarte, D. Â., Simões, S. C., da Costa, R. M., Rodríguez-Sarmiento, D. Y., Ferreira, P., Silva, C. A. A., Abrão, E. P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12074-3 · Cited by 110
G Protein-Coupled Receptors: Functional and Mechanistic Insights Through Altered Gene Expression
Rohrer, D. K., & Kobilka, B. K. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.35 · Cited by 109
Dual agonist occupancy of AT1-R–α2C-AR heterodimers results in atypical Gs-PKA signaling
Bellot, M., Galandrin, S., Boularan, C., Matthies, H. J. G., Despas, F., Denis, C., Javitch, J. A., Mazères, S., Sanni, S. J., Pons, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1766 · Cited by 109
GIRK Channel Activation Involves a Local Rearrangement of a Preformed G Protein Channel Complex
Riven, I., Iwanir, S., & Reuveny, E. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.017 · Cited by 108
Differential Signaling of the Endogenous Agonists at the β2-Adrenergic Receptor
Reiner, S., Ambrosio, M., Hoffmann, C., & Lohse, M. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175604 · Cited by 108
Ligand-independent CXCR2 Dimerization
Trettel, F., Bartolomeo, S. D., Lauro, C., Catalano, M., Ciotti, M. T., & Limatola, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306815200 · Cited by 108
Blechman, J., & Levkowitz, G. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00055 · Cited by 106
Novel Structural Insights into GPCR–β-Arrestin Interaction and Signaling
Ranjan, R., Dwivedi‐Agnihotri, H., Baidya, M., Kumar, M., & Shukla, A. K. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.05.008 · Cited by 106
β-Arrestin-mediated Signaling Regulates Protein Synthesis
DeWire, S. M., Kim, J., Whalen, E. J., Ahn, S., Chen, M., & Lefkowitz, R. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710515200 · Cited by 105
Kong, K. C., Butcher, A. J., McWilliams, P., Jones, D. W., Wess, J., Hamdan, F. F., Werry, T. D., Rosethorne, E. M., Charlton, S. J., Munson, S. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011651107 · Cited by 104
Emerging structural insights into biased GPCR signaling
Shukla, A. K., Singh, G., & Ghosh, E. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.10.001 · Cited by 104
Nikolaev, V. O., Hoffmann, C., Bünemann, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603266200 · Cited by 103
Watson, C., Chen, G., Irving, P. E., Way, J. M., Chen, W.-J., & Kenakin, T. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.6.1230 · Cited by 103
Self-citationPhosphorylation and regulation of a G protein–coupled receptor by protein kinase CK2
Torrecilla, I., Spragg, E. J., Poulin, B., McWilliams, P., Mistry, S. C., Blaukat, A., & Tobin, A. B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200610018 · Cited by 103
Merriam, L. A., Baran, C. N., Girard, B. M., Hardwick, J. C., May, V., & Parsons, R. L. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4999-12.2013 · Cited by 102
Kenakin, T. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108787 · Cited by 102
Self-citationMathiesen, J. M., Ulven, T., Martini, L., Gerlach, L. O., Heinemann, Á., & Kostenis, E. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010520 · Cited by 100
A2B adenosine receptor blockade inhibits growth of prostate cancer cells
Wei, Q., Costanzi, S., Balasubramanian, R., Gao, Z., & Jacobson, K. A. (2013) · Purinergic Signalling · doi:10.1007/s11302-012-9350-3 · Cited by 99
Arrestin 3 Mediates Endocytosis of CCR7 following Ligation of CCL19 but Not CCL21
Byers, M. A., Calloway, P. A., Shannon, L., Cunningham, H. D., Smith, S. E., Li, F., Fassold, B. C., & Vines, C. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4723 · Cited by 98
Stallaert, W., Dorn, J. F., van der Westhuizen, E. T., Audet, M., & Bouvier, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029420 · Cited by 98
Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor
Thompson, G. L., Lane, J. R., Coudrat, T., Sexton, P. M., Christopoulos, A., & Canals, M. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.098848 · Cited by 98
β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling
Rosanò, L., Cianfrocca, R., Tocci, P., Spinella, F., Castro, V. D., Spadaro, F., Salvati, E., Biroccio, A., Natali, P. G., & Bagnato, A. (2012) · Oncogene · doi:10.1038/onc.2012.527 · Cited by 97
Ikeda, K., Kobayashi, T., Kumanishi, T., Yano, R., Sora, I., & Niki, H. (2002) · Neuroscience Research · doi:10.1016/s0168-0102(02)00094-9 · Cited by 97
Armour, S. L., Foord, S., Kenakin, T., & Chen, W.-J. (1999) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00074-5 · Cited by 96
Self-citationDevost, D., Sleno, R., Pétrin, D., Zhang, A., Shinjo, Y., Okde, R., Aoki, J., Inoue, A., & Hébert, T. E. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.763854 · Cited by 95
Zocher, M., Fung, J. J., Kobilka, B. K., & Müller, D. J. (2012) · Structure · doi:10.1016/j.str.2012.05.010 · Cited by 94
On the analysis of ligand-directed signaling at G protein-coupled receptors
Ehlert, F. J. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0260-4 · Cited by 94
Charest, P. G., & Bouvier, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306589200 · Cited by 93
Gazi, L., Nickolls, S. A., & Strange, P. G. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705116 · Cited by 91
Kenakin, T. (1984) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1984.tb10753.x · Cited by 91
Self-citationConformational changes and drug action.
Burgen, A. S. (1981) · PubMed · Cited by 90
Endosomal GPCR signaling turned off by negative feedback actions of PKA and v-ATPase
Gidon, A., Al‐bataineh, M. M., Jean‐Alphonse, F., Stevenson, H. P., Watanabe, T., Louet, C., Khatri, A., Calero, G. A., Pastor‐Soler, N. M., Gardella, T. J., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1589 · Cited by 89
Schmid, C. L., Streicher, J. M., Groer, C. E., Munro, T. A., Zhou, L., & Bohn, L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.476234 · Cited by 89
Mori, T., Shibasaki, Y., Matsumoto, K., Shibasaki, M., Hasegawa, M., Wang, E., Masukawa, D., Yoshizawa, K., Horie, S., & Suzuki, T. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.204313 · Cited by 89
Hudson, B. D., Christiansen, E., Tikhonova, I. G., Grundmann, M., Kostenis, E., Adams, D. R., Ulven, T., & Milligan, G. (2012) · The FASEB Journal · doi:10.1096/fj.12-213314 · Cited by 89
Ryba, D. M., Li, J., Cowan, C. L., Russell, B., Wolska, B. M., & Solaro, R. J. (2017) · Circulation · doi:10.1161/circulationaha.116.024482 · Cited by 88
Newman‐Tancredi, A., Conte, C., Chaput, C., Verrièle, L., & Millan, M. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00022-1 · Cited by 87
Deshpande, D. A., Theriot, B. S., Penn, R. B., & Walker, J. K. L. (2008) · The FASEB Journal · doi:10.1096/fj.07-102459 · Cited by 87
Free, R. B., Chun, L. S., Moritz, A. E., Miller, B. N., Doyle, T. B., Conroy, J., Padron, A., Meade, J. A., Xiao, J., Hu, X., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.113.090563 · Cited by 87
Sharma, S., Rodriguez, A. L., Conn, P. J., & Lindsley, C. W. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.091 · Cited by 86
THE AFFINITY AND EFFICACY OF ONIUM SALTS ON THE FROG RECTUS ABDOMINIS
Barlow, R. B., Scott, N. C., & STEPHENSON, R. P. (1967) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1967.tb01989.x · Cited by 86
Davoren, J. E., Lee, C., Garnsey, M. R., Brodney, M. A., Cordes, J. S., Dlugolenski, K., Edgerton, J. R., Harris, A. R., Helal, C. J., Jenkinson, S. G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00544 · Cited by 86
Self-citationHeart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor
Felker, G. M., Butler, J., Collins, S. P., Cotter, G., Davison, B. A., Ezekowitz, J. A., Filippatos, G. S., Levy, P. D., Metra, M., Ponikowski, P. P., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.09.008 · Cited by 85
Strömberg, I., Popoli, P., Müller, C. E., Ferré, S., & Fuxé, K. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00288.x · Cited by 85
Recovery From Bronchoconstriction and Bronchodilator Tolerance
Haney, S. D., & Hancox, R. J. (2006) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:31:2:181 · Cited by 85
Hager, M. V., Johnson, L. M., Wootten, D. L., Sexton, P. M., & Gellman, S. H. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08323 · Cited by 85
A novel mechanism regulating human platelet activation by MMP-2–mediated PAR1 biased signaling
Sebastiano, M., Momi, S., Falcinelli, E., et al. (2016) · Blood · doi:10.1182/blood-2016-06-724245 · Cited by 85
Biased signaling at neural melanocortin receptors in regulation of energy homeostasis
Yang, L.-K., & Tao, Y. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.04.010 · Cited by 84
Roy, R. V., Ardeshirylajimi, A., Dinarvand, P., Yang, L., & Rezaie, A. R. (2016) · Blood · doi:10.1182/blood-2016-06-720581 · Cited by 83
Monasky, M. M., Taglieri, D. M., Henze, M., Warren, C. M., Utter, M. S., Soergel, D. G., Violin, J. D., & Solaro, R. J. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00327.2013 · Cited by 82
Refining Efficacy: Allosterism and Bias in G Protein-Coupled Receptor Signaling
Luttrell, L. M., & Kenakin, T. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-160-4_1 · Cited by 82
Self-citationDifferential activation of G‐proteins byμ‐opioid receptor agonists
Saidak, Z., Blake-Palmer, K. G., Hay, D. L., Northup, J. K., & Glass, M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706661 · Cited by 81
Violin, J. D., DeWire, S. M., Barnes, W. G., & Lefkowitz, R. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607956200 · Cited by 81
A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional Bias
Bolognini, D., Hodge, D., Nilsson, K. A., Petersson, A., Donnelly, I., Sergeev, E., König, G. M., Kostenis, E., Kurowska‐Stolarska, M., Miller, A. M., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.736157 · Cited by 81
A Novel Method for Analyzing Extremely Biased Agonism at G Protein–Coupled Receptors
Stahl, E. L., Zhou, L., Ehlert, F. J., & Bohn, L. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096503 · Cited by 80
G Protein and β-Arrestin Signaling Bias at the Ghrelin Receptor
Evron, T., Peterson, S. M., Urs, N. M., Bai, Y., Rochelle, L. K., Caron, M. G., & Barak, L. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.581397 · Cited by 80
The signaling signature of the neurotensin type 1 receptor with endogenous ligands
Besserer‐Offroy, É., Brouillette, R. L., Lavenus, S. B., Froehlich, U., Brumwell, A., Murza, A., Longpré, J., Marsault, É., Grandbois, M., Sarret, P., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.046 · Cited by 80
Temporal Bias: Time-Encoded Dynamic GPCR Signaling
Grundmann, M., & Kostenis, E. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.09.004 · Cited by 80
Peters, M. F., Knappenberger, K. S., Wilkins, D. E., Sygowski, L. A., Lazor, L. A., Liu, J., & Scott, C. W. (2007) · SLAS DISCOVERY · doi:10.1177/1087057106298637 · Cited by 79
Konkar, A. A., Zhu, Z., & Granneman, J. G. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39154-2 · Cited by 79
Sato, M., Horinouchi, T., Hutchinson, D. S., Evans, B. A., & Summers, R. J. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035337 · Cited by 78
A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer
Blättermann, S., Peters, L., Ottersbach, P. A., Böck, A., Kónya, V., Weaver, C. D., González, Á., Schröder, R. J., Tyagi, R., Luschnig, P., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.962 · Cited by 78
GPCRs and Signal Transducers: Interaction Stoichiometry
Gurevich, V. V., & Gurevich, E. V. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.04.002 · Cited by 78
Lin, Y., & Smrcka, A. V. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073072 · Cited by 77
Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor
Tschammer, N., Bollinger, S., Kenakin, T., & Gmeiner, P. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068106 · Cited by 77
Self-citationEmerging Approaches to GPCR Ligand Screening for Drug Discovery
Kumari, P., Ghosh, E., & Shukla, A. K. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.09.002 · Cited by 77
Chemokines and chemokine receptors: Update on utility and challenges for the clinician
Roy, I., Evans, D. B., & Dwinell, M. B. (2014) · Surgery · doi:10.1016/j.surg.2014.02.006 · Cited by 76
The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist
Erickson, C. E., Gul, R., Blessing, C. P., Nguyen, J. H., Liu, T., Pulakat, L., Bastepe, M., Jackson, E. K., & Andresen, B. T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071980 · Cited by 76
Pathway‐selective antagonism of proteinase activated receptor 2
Suen, J. Y., Cotterell, A. J., Lohman, R., Lim, J., Han, A., Yau, M., Liu, L., Cooper, M. A., Vesey, D. A., & Fairlie, D. P. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12757 · Cited by 75
Gong, K., Li, Z., Xu, M., Du, J., Lv, Z., & Zhang, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801313200 · Cited by 75
Dopamine promotes striatal neuronal apoptotic death via ERK signaling cascades
Chen, J., Rusnak, M., Lombroso, P. J., & Sidhu, A. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06590.x · Cited by 75
Yang, C.-H., Huang, H.-W., Chen, K., Chen, Y.-S., Sheen‐Chen, S., & Lin, C. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer291 · Cited by 75
Probing Heterotrimeric G Protein Activation: Applications to Biased Ligands
Denis, C., Saulière, A., Galandrin, S., Sénard, J., & Galès, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799040466 · Cited by 74
Insel, P. A., Wilderman, A. S., Zambon, A. C., Snead, A. N., Murray, F., Aroonsakool, N., McDonald, D., Zhou, S. M., McCann, T., Zhang, L., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.098129 · Cited by 74
Cardiac action of the first G protein biased small molecule apelin agonist
Read, C., Fitzpatrick, C. M., Yang, P. B., Kuc, R. E., Maguire, J. J., Glen, R. C., Foster, R., & Davenport, A. P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.07.018 · Cited by 74
Cannabinoid receptor ligand bias: implications in the central nervous system
Laprairie, R. B., Bagher, A. M., & Denovan‐Wright, E. M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.10.005 · Cited by 74
Konkar, A. A., Zhu, Z., & Granneman, J. G. (2000) · PubMed · Cited by 73
Budd, D. C., Willars, G. B., McDonald, J. E., & Tobin, A. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008827200 · Cited by 73
Biased Agonism of Three Different Cannabinoid Receptor Agonists in Mouse Brain Cortex
Dı́ez-Alarcia, R., Ibarra‐Lecue, I., López‐Cardona, A. P., Meana, J. J., Gutiérrez‐Adán, A., Callado, L. F., Agirregoitia, E., & Urigüen, L. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00415 · Cited by 73
Quantification of Functional Selectivity at the Human α1A-Adrenoceptor
Evans, B. A., Broxton, N. M., Merlin, J., Sato, M., Hutchinson, D. S., Christopoulos, A., & Summers, R. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067454 · Cited by 72
Scarduzio, M., Zimmerman, C. N., Jaunarajs, K. L. E., Wang, Q., Standaert, D. G., & McMahon, L. L. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.06.005 · Cited by 72
The Effective Application of Biased Signaling to New Drug Discovery
Kenakin, T. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099770 · Cited by 71
Self-citationUnderstanding the GPCR biased signaling through G protein and arrestin complex structures
Zhou, X. E., Melcher, K., & Xu, H. E. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.05.004 · Cited by 71
Onaran, H. O., Ambrosio, C., Uğur, Ö., Koncz, E. M., Grò, M. C., Vezzi, V., Rajagopal, S., & Costa, T. (2017) · Scientific Reports · doi:10.1038/srep44247 · Cited by 71
β-Arrestin1–Biased β 1 -Adrenergic Receptor Signaling Regulates MicroRNA Processing
Kim, I., Wang, Y., Park, K., Tang, Y., Teoh, J., Vinson, J., Traynham, C. J., Pironti, G., Mao, L., Su, H., et al. (2013) · Circulation Research · doi:10.1161/circresaha.114.302766 · Cited by 70
Spinella, F., Rosanò, L., Castro, V. D., Nicotra, M. R., Natali, P. G., & Bagnato, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0315 · Cited by 70
Quantification of adenosine A 1 receptor biased agonism: Implications for drug discovery
Baltos, J., Gregory, K. J., White, P. J., Sexton, P. M., Christopoulos, A., & May, L. T. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.013 · Cited by 70
Pradhan, A. A. A., Perroy, J., Walwyn, W. M., Smith, M. L., Vicente‐Sánchez, A., Segura, L., Bana, A., Kieffer, B. L., & Evans, C. J. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4124-15.2016 · Cited by 69
Binding Kinetics and Pathways of Ligands to GPCRs
Straßer, A., Wittmann, H., & Seifert, R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.005 · Cited by 69
PAM-Antagonists: A Better Way to Block Pathological Receptor Signaling?
Kenakin, T., & Strachan, R. T. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.05.001 · Cited by 69
Self-citationDiscovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure
Möller, D., Banerjee, A., Uzuneser, T. C., Skultety, M., Huth, T., Plouffe, B., Hübner, H., Alzheimer, C., Friedland, K., Müller, C. P., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01857 · Cited by 68
What is pharmacological ‘affinity’? Relevance to biased agonism and antagonism
Kenakin, T. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.06.003 · Cited by 66
Self-citationβ-Arrestin-Selective G Protein-Coupled Receptor Agonists Engender Unique Biological Efficacy in Vivo
Gesty‐Palmer, D., Yuan, L., Martin, B., Wood, W. H., Lee, M., Janech, M. G., Tsoi, L. C., Zheng, W. J., Luttrell, L. M., & Maudsley, S. R. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1091 · Cited by 65
Molecular Determinants of Allosteric Modulation at the M1 Muscarinic Acetylcholine Receptor
Abdul‐Ridha, A., López, L., Keov, P., Thal, D. M., Mistry, S. N., Sexton, P. M., Lane, J. R., Canals, M., & Christopoulos, A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.539080 · Cited by 63
Soto, A. G., Smith, T. H., Chen, B., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508838112 · Cited by 63
Role of beta-arrestin 2 downstream of dopamine receptors in the basal ganglia
Del’Guidice, T. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00058 · Cited by 62
New paradigms in adenosine receptor pharmacology: allostery, oligomerization and biased agonism
Vecchio, E. A., Baltos, J., Nguyen, A. T. N., Christopoulos, A., White, P. J., & May, L. T. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14337 · Cited by 61
Trinquet, E., Bouhelal, R., & Dietz, M. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.608658 · Cited by 60
Alvarez‐Curto, E., Prihandoko, R., Tautermann, C. S., Zwier, J. M., Pediani, J. D., Lohse, M. J., Hoffmann, C., Tobin, A. B., & Milligan, G. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.074674 · Cited by 60
Naylor, J., Suckow, A. T., Seth, A., Baker, D. J., Sermadiras, I., Ravn, P., Howes, R., Li, J., Snaith, M. R., Coghlan, M. P., et al. (2016) · Biochemical Journal · doi:10.1042/bcj20160476 · Cited by 60
Choreographing the adenylyl cyclase signalosome: sorting out the partners and the steps
Ostrom, R. S., Bogard, A. S., Gros, R., & Feldman, R. D. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0696-9 · Cited by 59
Research works printed but not linked: 39
- Appleton, 2013, Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity, Methods Enzymol, 522, 229, 10.1016/B978-0-12-407865-9.00013-3 · doi:10.1016/b978-0-12-407865-9.00013-3
- Audet, 2008, Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins, J Biol Chem, 283, 15078, 10.1074/jbc.M707941200 · doi:10.1074/jbc.m707941200
- Aurelio, 2018, A structure-activity relationship study of bitopic N6-substituted adenosine derivatives as biased adenosine A1 receptor agonists, J Med Chem, 61, 2087, 10.1021/acs.jmedchem.8b00047 · doi:10.1021/acs.jmedchem.8b00047
- Coffa, 2011, A single mutation in arrestin-2 prevents ERK1/2 activation by reducing c-Raf1 binding, Biochemistry, 50, 6951, 10.1021/bi200745k · doi:10.1021/bi200745k
- Coffman, 1997, A genetic approach for studying the physiology of the type 1A (AT1A) angiotensin receptor, Semin Nephrol, 17, 404
- Cook, 2015, Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics, Br J Pharmacol, 172, 185, 10.1111/bph.12937 · doi:10.1111/bph.12937
- Coward, 1998, Controlling signaling with a specifically designed Gi-coupled receptor in transgenic mice, Nat Biotechnol, 17, 165
- Daugvilaite, 2017, Biased agonism and allosteric modulation of G protein-coupled receptor 183 - a 7TM receptor also known as Epstein-Barr virus-induced gene 2, Br J Pharmacol, 174, 2031, 10.1111/bph.13801 · doi:10.1111/bph.13801
- Fang, 2008, Label-free optical biosensor for ligand-directed functional selectivity acting on beta(2) adrenoceptor in living cells, FEBS Lett, 582, 558, 10.1016/j.febslet.2008.01.021 · doi:10.1016/j.febslet.2008.01.021
- Ferrari, 2017, In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403, Pharmacol Res Perspect, 5, 10.1002/prp2.333 · doi:10.1002/prp2.333
- Fisher, 1993, Selective signaling via unique M1 muscarinic agonists, Ann N Y Acad Sci, 695, 300, 10.1111/j.1749-6632.1993.tb23070.x · doi:10.1111/j.1749-6632.1993.tb23070.x
- Gesty-Palmer, 2011, ‘Biasing’ the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?, Br J Pharmacol, 164, 59, 10.1111/j.1476-5381.2011.01450.x · doi:10.1111/j.1476-5381.2011.01450.x
- Heldman, 1996, Pharmacological basis for functional selectivity of partial muscarinic receptor agonists, Eur J Pharmacol, 297, 283, 10.1016/0014-2999(95)00745-8 · doi:10.1016/0014-2999(95)00745-8
- Hoffmann, 2008, Agonist-selective, receptor-specific interaction of human P2Y receptors with β-arrestin-1 and -2, J Biol Chem, 283, 30933, 10.1074/jbc.M801472200 · doi:10.1074/jbc.m801472200
- Hou, 2016, Label-free cell phenotypic profiling and pathway deconvolution of neurotensin receptor-1, Pharmacol Res, 108, 39, 10.1016/j.phrs.2016.04.018 · doi:10.1016/j.phrs.2016.04.018
- Jozwiak, 2010, The effect of stereochemistry on the thermodynamic characteristics of the binding of fenoterol stereoisomers to the beta(2)-adrenoceptor, Biochem Pharmacol, 79, 1610, 10.1016/j.bcp.2010.01.035 · doi:10.1016/j.bcp.2010.01.035
- Kenakin, 2012, Casting a wider net: whole-cell assays to capture varied and biased signaling, Mol Pharmacol, 82, 571, 10.1124/mol.112.081117 · doi:10.1124/mol.112.081117
- Kenakin, 1985, Prenalterol as a selective cardiostimulant: differences between organ and receptor selectivity, J Cardiovasc Pharmacol, 7, 208, 10.1097/00005344-198501000-00033 · doi:10.1097/00005344-198501000-00033
- Kenakin, 2016, Synoptic pharmacology: detecting and assessing the pharmacological significance of ligands for orphan receptors, Pharmacol Res, 114, 284, 10.1016/j.phrs.2016.01.022 · doi:10.1016/j.phrs.2016.01.022
- Kenakin, 1991, The relative efficiency of beta adrenoceptor coupling to myocardial inotropy and diastolic relaxation: organ-selective treatment for diastolic dysfunction, J Pharmacol Exp Ther, 257, 1189, 10.1016/S0022-3565(25)24731-0 · doi:10.1016/s0022-3565(25)24731-0
- Lawler, 1994, Discrete functional selectivity of drugs: OPC-14597, a selective antagonist for post-synaptic dopamine D2 receptors (Abstract), Soc Neurosci Abstr, 20, 525
- Longabaugh, 1988, Decreased stimulatory guanosine triphosphate binding protein in dogs with pressure-overload left ventricular failure, J Clin Invest, 81, 420, 10.1172/JCI113335 · doi:10.1172/jci113335
- Maguire, 2016, Evidence for biased agonists and antagonists at the endothelin receptors, Life Sci, 159, 30, 10.1016/j.lfs.2016.02.069 · doi:10.1016/j.lfs.2016.02.069
- Maillet, 2007, A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties, FASEB J, 21, 2124, 10.1096/fj.06-7683com · doi:10.1096/fj.06-7683com
- McAnally, 2017, A systematic approach to identify biased agonists of the apelin receptor through high-throughput screening, SLAS Discov, 22, 867, 10.1177/2472555217699158 · doi:10.1177/2472555217699158
- Michal, 2007, Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins, J Pharmacol Exp Ther, 320, 607, 10.1124/jpet.106.114314 · doi:10.1124/jpet.106.114314
- Milanos, 2016, Discovery and characterization of biased allosteric agonists of the chemokine receptor CXCR3, J Med Chem, 59, 2222, 10.1021/acs.jmedchem.5b01965 · doi:10.1021/acs.jmedchem.5b01965
- Milanos, 2016, Identification of two distinct sites for antagonist and biased agonist binding to the human chemokine receptor CXCR3, Angew Chem Int Ed Engl, 55, 15277, 10.1002/anie.201607831 · doi:10.1002/anie.201607831
- Mottola, 1991, Dihydrexidine, a selective dopamine receptor agonist that may discriminate postsynaptic D2 receptors, Abstr Soc Neurosci, 17, 818
- Nasman, 2001, Role of G-protein availability in differential signaling by alpha 2-adrenoceptors, Biochem Pharmacol, 62, 913, 10.1016/S0006-2952(01)00730-4 · doi:10.1016/s0006-2952(01)00730-4
- Ogawa, 2016, Structural optimization and structure-functional selectivity relationship studies of G protein-biased EP2 receptor agonists, Bioorg Med Chem Lett, 26, 2446, 10.1016/j.bmcl.2016.03.110 · doi:10.1016/j.bmcl.2016.03.110
- Peverelli, 2013, Specific roles of G(i) protein family members revealed by dissecting SST5 coupling in human pituitary cells, J Cell Sci, 126, 638, 10.1242/jcs.116434 · doi:10.1242/jcs.116434
- Roerig, 1992, Identification of three separate guanine nucleotide-binding proteins that interact with the delta-opioid receptor in NG108-15 neuroblastoma x glioma hybrid cells, Mol Pharmacol, 41, 822, 10.1016/S0026-895X(25)09122-9 · doi:10.1016/s0026-895x(25)09122-9
- Seo, 2011, Identification of arrestin-3-specific residues necessary for JNK3 kinase activation, J Biol Chem, 286, 27894, 10.1074/jbc.M111.260448 · doi:10.1074/jbc.m111.260448
- Tang, 1998, Native protein fluctuations: the conformational-motion temperature and the inverse correlation of protein flexibility with protein stability, J Biomol Struct Dyn, 16, 397, 10.1080/07391102.1998.10508256 · doi:10.1080/07391102.1998.10508256
- Tucek, 1997, Is the R and R dichotomy real?, Trends Pharmacol Sci, 18, 414, 10.1016/S0165-6147(97)90672-6 · doi:10.1016/s0165-6147(97)90672-6
- Ward, 1995, Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles, J Med Chem, 38, 3469, 10.1021/jm00018a007 · doi:10.1021/jm00018a007
- Woo, 2017, Biased agonism at the angiotensin receptor: blocker and calcium sensitizer at the same time, Circulation, 135, 1071, 10.1161/CIRCULATIONAHA.117.027276 · doi:10.1161/circulationaha.117.027276
- Zhou, 2018, An operational model for GPCR homodimers and its application in the analysis of biased signaling, Drug Discov Today, 23, 1591, 10.1016/j.drudis.2018.04.004 · doi:10.1016/j.drudis.2018.04.004
Cited by
TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome
Olsen, R. H. J., DiBerto, J. F., English, J. G., Glaudin, A. M., Krumm, B. E., Slocum, S. T., Che, T., Gavin, A. C., McCorvy, J. D., Roth, B. L., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0535-8 · Cited by 544
Review of the Endocannabinoid System
Lu, H.-C., & Mackie, K. (2021) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.016 · Cited by 491
GPCR activation mechanisms across classes and macro/microscales
Hauser, A. S., Kooistra, A. J., Munk, C., Heydenreich, F. M., Veprintsev, D. B., Bouvier, M., Babu, M. M., & Gloriam, D. E. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00674-7 · Cited by 301
Virtual discovery of melatonin receptor ligands to modulate circadian rhythms
Stein, R. M., Kang, H. J., McCorvy, J. D., Glatfelter, G. C., Jones, A. J., Che, T., Slocum, S., Huang, X.-P., Savych, O., Moroz, Y. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2027-0 · Cited by 298
Self-citationMolecular basis of β-arrestin coupling to formoterol-bound β1-adrenoceptor
Lee, Y., Warne, T., Nehmé, R., Pandey, S., Dwivedi-Agnihotri, H., Chaturvedi, M., Edwards, P. C., García-Nafría, J., Leslie, A. G. W., Shukla, A. K., et al. (2020) · Nature · doi:10.1038/s41586-020-2419-1 · Cited by 295
Metadata
- Authors
- Kenakin, T.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 71
- Issue
- 2
- Pages
- 267-315
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2923681300
- Cited by
- 294
- References
- 525
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.